References: 

• 1. Knowles TP, Vendruscolo M, Dobson CM (2014) The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15: 384–396.    
• 2. Hardy JA, Higgins GA (1992) Alzheimers disease-the amyloid cascade hyopothesis. Science 256: 184–185.    
• 3. Arriagada PV, Growdon JH, Hedleywhyte ET, et al. (1992) Neurofibrillary tangles but not senile plaques parellel duration and severity of Alzheimers disease. Neurology 42: 631–639.    
• 4. Terry RD, Masliah E, Salmon DP, et al. (1991) Physical basis of cognitve alterations in Alzheimers disease-synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572–580.    
• 5. Viola KL, Sbarboro J, Sureka R, et al. (2015) Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat Nanotechnol 10: 91–98.    
• 6. Hyman B, Tanzi R (1992) Amyloid, dementia and Alzheimer's disease. Curr Opin Neurol Neurosur 5: 88–93.
• 7. Cummings BJ, Pike CJ, Shankle R, et al. (1996) b-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17: 921–933.    
• 8. Cummings JL, Morstorf T, Zhong K (2014) Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 6: 37.    
• 9. Goure WF, Krafft GA, Jerecic J, et al. (2014) Targeting the proper amyloid-β neuronal toxins: A path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther 6: 42.    
• 10. Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76: 185–205.    
• 11. Karran E, Hardy J (2014) Antiamyloid therapy for Alzheimer's disease-are we on the right road? New Engl J Med 370: 377–378.    
• 12. Frackowiak J, Zoltowska A, Wisniewski HM (1994) Nonfibrillar β-amyloid protein is associated with smooth-muscle cells of vessel walls in Alzheimer disease. J Neuropath Exp Neur 53: 637–645.    
• 13. Oda T, Pasinetti GM, Osterburg HH, et al. (1994) Purification and characterization of brain clusterin. Biochem Bioph Res Co 204: 1131–1136.    
• 14. Oda T, Wals P, Osterburg HH, et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid β peptide (Aβ(1-42)) and forms slowly sedimenting Aβ complexes that cuase oxidative stress. Exp Neurol 136: 22–31.    
• 15. Esparza TJ, Zhao H, Cirrito JR, et al. (2013) Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104–119.    
• 16. Gong YS, Chang L, Viola KL, et al. (2003) Alzheimer's disease-affected brain: Presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. P Natl Acad Sci USA 100: 10417–10422.    
• 17. Kayed R, Head E, Thompson JL, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486–489.    
• 18. Noguchi A, Matsumura S, Dezawa M, et al. (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. J Biol Chem 284: 32895–32905.    
• 19. Pham E, Crews L, Ubhi K, et al. (2010) Progressive accumulation of amyloid-β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 277: 3051–3067.    
• 20. Gyure KA, Durham R, Stewart WF, et al. (2001) Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489–492.
• 21. Lacor PN, Buniel MC, Chang L, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191–10200.    
• 22. Lesne SE, Sherman MA, Grant M, et al. (2013) Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 136: 1383–1398.    
• 23. Georganopoulou DG, Chang L, Nam JM, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. P Natl Acad Sci USA 102: 2273–2276.    
• 24. Bruggink KA, Jongbloed W, Biemans EALM, et al. (2013) Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem 433: 112–120.    
• 25. Englund H, Gunnarsson MD, Brundin RM, et al. (2009) Oligomerization partially explains the lowering of Aβ42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis 6: 139–147.    
• 26. Fukumoto H, Tokuda T, Kasai T, et al. (2010) High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716–2726.    
• 27. Gao CM, Yam AY, Wang X, et al. (2010) Aβ40 Oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One 5: e15725.    
• 28. Herskovits AZ, Locascio JJ, Peskind ER, et al. (2013) A luminex assay detects amyloid-β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8: e67898.    
• 29. Holtta M, Hansson O, Andreasson U, et al. (2013) Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One 8: e66381.    
• 30. Jongbloed W, Bruggink KA, Kester MI, et al. (2015) Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease. J Alzheimers Dis 45: 35–43.    
• 31. Santos AN, Ewers M, Minthon L, et al. (2012) Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29: 171–176.    
• 32. Lesne S, Koh MT, Kotilinek L, et al. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352–357.    
• 33. Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. P Natl Acad Sci USA 106: 14745–14750.    
• 34. Quist A, Doudevski L, Lin H, et al. (2005) Amyloid ion channels: A common structural link for protein-misfolding disease. P Natl Acad Sci USA 102: 10427–10432.    
• 35. Shankar GM, Bloodgood BL, Townsend M, et al. (2007) Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866–2875.    
• 36. Shankar GM, Li S, Mehta TH, et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837–842.    
• 37. Townsend M, Shankar GM, Mehta T, et al. (2006) Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572: 477–492.    
• 38. Lambert MP, Barlow AK, Chromy BA, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. P Natl Acad Sci USA 95: 6448–6453.    
• 39. Walsh DM, Klyubin I, Fadeeva JV, et al. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535–539.    
• 40. Zhao J, Li A, Rajsombath M, et al. (2018) Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. iScience 6: 138–150.    
• 41. De Felice FG, Wu D, Lambert MP, et al. (2008) Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 29: 1334–1347.    
• 42. Ma QL, Yang F, Rosario ER, et al. (2009) β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29: 9078–9089.    
• 43. Resende R, Ferreiro E, Pereira C, et al. (2008) ER stress is involved in Aβ-induced GSK-3β activation and tau phosphorylation. J Neurosci Res 86: 2091–2099.    
• 44. Tomiyama T, Matsuyama S, Iso H, et al. (2010) A mouse model of amyloid-β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30: 4845–4856.    
• 45. Zempel H, Thies E, Mandelkow E, et al. (2010) A Oligomers Cause Localized Ca²⁺ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines. J Neurosci 30: 11938–11950.    
• 46. Heinitz K, Beck M, Schliebs R, et al. (2006) Toxicity mediated by soluble oligomers of β-amyloid(1‑42) on cholinergic SN56.B5.G4 cells. J Neurochem 98: 1930–1945.    
• 47. Nunes-Tavares N, Santos LE, Stutz B, et al. (2012) Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-β peptide oligomers. J Biol Chem 287: 19377–19385.    
• 48. De Felice FG, Velasco PT, Lambert MP, et al. (2007) Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282: 11590–11601.    
• 49. Longo VD, Viola KL, Klein WL, et al. (2000) Reversible inactivation of superoxide-sensitive aconitase in Aβ1-42-treated neuronal cell lines. J Neurochem 75: 1977–1985.
• 50. Sponne I, Fifre A, Drouet B, et al. (2003) Apoptotic neuronal cell death induced by the non-fibrillar amyloid-β peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J Biol Chem 278: 3437–3445.    
• 51. Tabner BJ, El-Agnaf OMA, Turnbull S, et al. (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 280: 35789–35792.    
• 52. Alberdi E, Wyssenbach A, Alberdi M, et al. (2013) Ca²⁺-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer's disease. Aging Cell 12: 292–302.    
• 53. Nishitsuji K, Tomiyama T, Ishibashi K, et al. (2009) The E693Δ mutation in amyloid precursor protein increases intracellular accumulation of amyloid β oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 174: 957–969.    
• 54. Lacor PN, Buniel MC, Furlow PW, et al. (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796–807.    
• 55. Roselli F (2005) Soluble β-Amyloid_1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25: 11061–11070.    
• 56. Snyder EM, Nong Y, Almeida CG, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8: 1051–1058.    
• 57. Zhao WQ, De Felice FG, Fernandez S, et al. (2007) Amyloid β oligomers induce impairment of neuronal insulin receptors. FASEB J 22: 246–260.
• 58. De Felice FG, Vieira MN, Bomfim TR, et al. (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci USA 106: 1971–1976.    
• 59. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. (2009) Oligomeric amyloid-β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. P Natl Acad Sci USA 106: 4012–4017.    
• 60. Decker H, Lo KY, Unger SM, et al. (2010) Amyloid-Peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3 in primary cultured hippocampal neurons. J Neurosci 30: 9166–9171.    
• 61. Pigino G, Morfini G, Atagi Y, et al. (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid β. P Natl Acad Sci USA 106: 5907–5912.    
• 62. Poon WW, Blurton-Jones M, Tu CH, et al. (2011) β-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging 32: 821–833.    
• 63. Hu J, Akama KT, Krafft GA, et al. (1998) Amyloid-β peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195–206.    
• 64. Jimenez S, Baglietto-Vargas D, Caballero C, et al. (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: Age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28: 11650–11661.    
• 65. Bhaskar K, Miller M, Chludzinski A, et al. (2009) The PI3K-Akt-mTOR pathway regulates a oligomer induced neuronal cell cycle events. Mol Neurodegener 4: 1–18.    
• 66. Varvel NH, Bhaskar K, Patil AR, et al. (2008) Aβ oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci 28: 10786–10793.    
• 67. Kim HJ, Chae SC, Lee DK, et al. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid β protein. FASEB J 17: 118–120.    
• 68. Roher AE, Lowenson JD, Clarke S, et al. (1993) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. P Natl Acad Sci USA 90: 10836.    
• 69. Näslund J, Schierhorn A, Hellman U, et al. (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. P Natl Acad Sci USA 91: 8378.    
• 70. Vandersteen A, Hubin E, Sarroukh R, et al. (2012) A comparative analysis of the aggregation behavior of amyloid-β peptide variants. FEBS Lett 586: 4088–4093.    
• 71. Barrow CJ, Yasuda A, Kenny PTM, et al. (1992) Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease: Analysis of circular dichroism spectra. J Mol Biol 225: 1075–1093.    
• 72. Barrow CJ, Zagorski MG (1991) Solution structures of β peptide and its constituent fragments: Relation to amyloid deposition. Science 253: 179–182.    
• 73. Inouye H, Fraser PE, Kirschner DA (1993) Structure of β-crystallite assemblies formed by Alzheimer β-amyloid protein analogs-analysis by x-ray diffraction. Biophys J 64: 502–519.    
• 74. Torok M, Milton S, Kayed R, et al. (2002) Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 277: 40810–40815.    
• 75. Antzutkin ON, Balbach JJ, Leapman RD, et al. (2000) Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils. P Natl Acad Sci USA 97: 13045–13050.    
• 76. Petkova AT, Leapman RD, Guo ZH, et al. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307: 262–265.    
• 77. Tycko R (2006) Solid-state NMR as a probe of amyloid structure. Protein Peptide Lett 13: 229–234.    
• 78. Pastor MT, Kuemmerer N, Schubert V, et al. (2008) Amyloid toxicity is independent of polypeptide sequence, length and chirality. J Mol Biol 375: 695–707.    
• 79. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333–366.    
• 80. Xue WF, Homans SW, Radford SE (2008) Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci USA 105: 8926–8931.    
• 81. Murphy R (2007) Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. BBA-Biomembranes 1768: 1923–1934.    
• 82. Ghosh P, Vaidya A, Kumar A, et al. (2016) Determination of critical nucleation number for a single nucleation amyloid-β aggregation model. Math Biosci 273: 70–79.    
• 83. Garai K, Sahoo B, Sengupta P, et al. (2008) Quasihomogeneous nucleation of amyloid β yields numerical bounds for the critical radius, the surface tension, and the free energy barrier for nucleus formation. J Chem Phys 128: 045102.    
• 84. Novo M, Freire S, Al-Soufi W (2018) Critical aggregation concentration for the formation of early Amyloid-β(1-42) oligomers. Sci Rep 8: 1783.    
• 85. Xue C, Lin TY, Chang D, et al. (2017) Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation. Roy Soc Open Sci 4: 160696.    
• 86. Kodali R, Wetzel R (2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struc Biol 17: 48–57.    
• 87. Kodali R, Williams AD, Chemuru S, et al. (2010) Aβ(1-40) forms five distinct amyloid structures whose β-sheet contents and fibril stabilities are correlated. J Mol Biol 401: 503–517.    
• 88. Meinhardt J, Sachse C, Hortschansky P, et al. (2009) Aβ(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol 386: 869–877.    
• 89. Tycko R (2015) Amyloid polymorphism: Structural basis and neurobiological relevance. Neuron 86: 632–645.    
• 90. Colletier JP, Laganowsky A, Landau M, et al. (2011) Molecular basis for amyloid-β polymorphism. P Natl Acad Sci USA 108: 16938–16943.    
• 91. Crowther RA, Goedert M (2000) Abnormal Tau-containing filaments in Neurodegenerative Disease. J Struct Biol 130: 271–279.    
• 92. Lu JX, Qiang W, Yau WM, et al. (2013) Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154: 1257–1268.    
• 93. Qiang W, Yau WM, Lu JX, et al. (2017) Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes. Nature 541: 217–221.    
• 94. Paravastu AK, Qahwash I, Leapman RD, et al. (2009) Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. P Natl Acad Sci USA 106: 7443–7448.    
• 95. Yates EA, Legleiter J (2014) Preparation protocols of Aβ(1-40) promote the formation of polymorphic aggregates and altered interactions with lipid bilayers. Biochemistry 53: 7038–7050.    
• 96. Teplow DB (2013) On the subject of rigor in the study of amyloid β-protein assembly. Alzheimers Res Ther 5: 39.    
• 97. Lee MC, Yu WC, Shih YH, et al. (2018) Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer's disease. Sci Rep 8: 1–16.    
• 98. Ryan DA, Narrow WC, Federoff HJ, et al. (2010) An improved method for generating consistent soluble amyloid-β oligomer preparations for in vitro neurotoxicity studies. J Neurosci Meth 190: 171–179.    
• 99. Barghorn S, Nimmrich V, Striebinger A, et al. (2005) Globular amyloid β-peptide1-42 oligomer-A homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95: 834–847.    
• 100. Thibaudeau TA, Anderson RT, Smith DM (2018) A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat Commun 9: 1097.    
• 101. Stine WB, Dahlgren KN, Krafft GA, et al. (2003) In vitro characterization of conditions for amyloid-b peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612–11622.    
• 102. Stine WB, Jungbauer L, Yu C, et al. (2011) Preparing synthetic Aβ in different aggregation states, In: Roberson ED (editor.), Alzheimer's Disease and Frontotemporal Dementia. Methods in Molecular Biology (Methods and Protocols), Totowa, NJ: Humana Press, 13–32.
• 103. Benninger RJ, David T (1983) An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments. Brain Res Rev 287: 173–196.
• 104. Ryan TM, Caine J, Mertens HDT, et al. (2013) Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ 1: e73.    
• 105. Bitan G, Lomakin A, Teplow DB (2001) Amyloid β-protein oligomerization: Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 276: 35176–35184.    
• 106. Lesne SE (2013) Breaking the code of amyloid-β oligomers. Int J Cell Biol 2013: 950783.
• 107. Sengupta U, Nilson AN, Kayed R (2016) The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6: 42–49.    
• 108. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15: 349–357.    
• 109. Ferreira ST, Lourenco MV, Oliveira MM, et al. (2015) Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci 9: 191.
• 110. Cline EN, Bicca MA, Viola KL, et al. (2018) The amyloid-β oligomer hypothesis: Beginning of the third decade. J Alzheimers Dis 64: S567–S610.    
• 111. Brody DL, Jiang H, Wildburger N, et al. (2017) Non-canonical soluble amyloid-β aggregates and plaque buffering: Controversies and future directions for target discovery in Alzheimer's disease. Alzheimers Res Ther 9: 62.    
• 112. Sherman MA, LaCroix M, Amar F, et al. (2016) Soluble conformers of Aβ and Tau alter selective proteins governing axonal transport. J Neurosci 36: 9647–9658.    
• 113. O'Malley TT, Oktaviani NA, Zhang D, et al. (2014) Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem J 461: 413–426.    
• 114. Cheng IH, Scearce-Levie K, Legleiter J, et al. (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282: 23818–23828.    
• 115. Amar F, Sherman MA, Rush T, et al. (2017) The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. Sci Signal 10: eaal2021.    
• 116. Liu P, Reed MN, Kotilinek LA, et al. (2015) Quaternary structure defines a large class of amyloid-β oligomers neutralized by sequestration. Cell Rep 11: 1760–1771.    
• 117. Knight EM, Kim SH, Kottwitz JC, et al. (2016) Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes. Neurol Neuroimmunol Neuroinflamm 3: e237.    
• 118. Velasco PT, Heffern MC, Sebollela A, et al. (2012) Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci 3: 972–981.    
• 119. Ryan TM, Roberts BR, McColl G, et al. (2015) Stabilization of nontoxic Aβ-oligomers: Insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. J Neurosci 35: 2871–2884.    
• 120. Ferreira IL, Ferreiro E, Schmidt J, et al. (2015) Aβ and NMDAR activation cause mitochondrial dysfunction involving ER calcium release. Neurobiol Aging 36: 680–692.    
• 121. Barz B, Liao Q, Strodel B (2018) Pathways of amyloid-β aggregation depend on oligomer shape. J Am Chem Soc 140: 319–327.    
• 122. Brito-Moreira J, Lourenco MV, Oliveira MM, et al. (2017) Interaction of amyloid-β (Aβ) oligomers with neurexin 2 and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem 292: 7327–7337.    
• 123. Figueiredo CP, Clarke JR, Ledo JH, et al. (2013) Memantine rescues transient cognitive impairment caused by high-molecular-weight Aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 33: 9626–9317.    
• 124. Upadhaya AR, Lungrin I, Yamaguchi H, et al. (2012) High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16: 287–295.    
• 125. Mc Donald JM, O'Malley TT, Liu W, et al. (2015) The aqueous phase of Alzheimer's disease brain contains assemblies built from similar to 4 and similar to 7 kDa Aβ species. Alzheimers Dement 11: 1286–1305.    
• 126. Savioz A, Giannakopoulos P, Herrmann FR, et al. (2016) A study of Aβ oligomers in the temporal cortex and cerebellum of patients with neuropathologically confirmed Alzheimer's disease compared to aged controls. Neurodegener Dis 16: 398–406.    
• 127. Breydo L, Kurouski D, Rasool S, et al. (2016) Structural differences between amyloid β oligomers. Biochem Bioph Res Co 477: 700–705.    
• 128. Watanabe-Nakayama T, Ono K, Itami M, et al. (2016) High-speed atomic force microscopy reveals structural dynamics of amyloid β(1-42) aggregates. P Natl Acad Sci USA 113: 5835–5840.    
• 129. Matsumura S, Shinoda K, Yamada M, et al. (2011) Two distinct amyloid β-protein (Aβ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J Biol Chem 286: 11555–11562.    
• 130. Miller Y, Ma B, Nussinov R (2010) Polymorphism in Alzheimer Aβ amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev 110: 4820–4838.    
• 131. Bernstein SL, Dupuis NF, Lazo ND, et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1: 326–331.    
• 132. Economou NJ, Giammona MJ, Do TD, et al. (2016) Amyloid β-protein assembly and Alzheimer's disease: Dodecamers of Aβ42, but not of Aβ40, seed fibril formation. J Am Chem Soc 138: 1772–1775.    
• 133. Shamitko-Klingensmith N, Boyd JW, Legleiter J (2016) Microtubule modification influences cellular response to amyloid-β exposure. AIMS Biophysics 3: 261–285.    
• 134. Yates EA, Cucco EM, Legleiter J (2011) Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces. ACS Chem Neurosci 2: 294–307.    
• 135. Yates EA, Owens SL, Lynch MF, et al. (2013) Specific domains of Aβ facilitate aggregation on and association with lipid bilayers. J Mol Biol 425: 1915–1933.    
• 136. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639–29643.    
• 137. Chromy BA, Nowak RJ, Lambert MP, et al. (2003) Self-assembly of Aβ(1-42) into globular neurotoxins. Biochemistry 42: 12749–12760.    
• 138. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27: 570–575.    
• 139. Lee EB, Leng LZ, Zhang B, et al. (2006) Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 281: 4292–4299.    
• 140. Lambert MP, Velasco PT, Chang L, et al. (2007) Monoclonal antibodies that target pathological assemblies of Aβ. J Neurochem 100: 23–35.    
• 141. Hayden EY, Conovaloff JL, Mason A, et al. (2017) Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes. Anal Biochem 518: 78–85.    
• 142. Ono K, Li L, Takamura Y, et al. (2012) Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem 287: 14631–14643.    
• 143. Bitan G, Kirkitadze MD, Lomakin A, et al. (2003) Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. P Natl Acad Sci USA 100: 330–335.    
• 144. Al-Hilaly YK, Williams TL, Stewart-Parker M, et al. (2013) A central role for dityrosine crosslinking of Amyloid-β in Alzheimer's disease. Acta Neuropathol Commun 1: 83.    
• 145. Bush AI (2013) The metal theory of Alzheimer's disease. J Alzheimers Dis 33: S277–S281.
• 146. Butterfield DA, Boyd-Kimball D (2018) Oxidative stress, amyloid-β peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer's disease. J Alzheimers Dis 62: 1345–1367.    
• 147. Smith DP, Ciccotosto GD, Tew DJ, et al. (2007) Concentration dependent Cu²⁺ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-β peptide. Biochemistry 46: 2881–2891.    
• 148. Ryan TM, Kirby N, Mertens HDT, et al. (2015) Small angle X-ray scattering analysis of Cu²⁺-induced oligomers of the Alzheimer's amyloid β peptide. Metallomics 7: 536–543.    
• 149. Takano K, Endo S, Mukaiyama A, et al. (2006) Structure of amyloid β fragments in aqueous environments. FEBS J 273: 150–158.    
• 150. Streltsov VA, Varghese JN, Masters CL, et al. (2011) Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 31: 1419–1426.    
• 151. Liu C, Sawaya MR, Cheng PN, et al. (2011) Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic β-sheet mimics. J Am Chem Soc 133: 6736–6744.    
• 152. Pham JD, Chim N, Goulding CW, et al. (2013) Structures of oligomers of a peptide from β-amyloid. J Am Chem Soc 135: 12460–12467.    
• 153. Spencer RK, Li H, Nowick JS (2014) X-ray crystallographic structures of trimers and higher-order oligomeric sssemblies of a peptide derived from Aβ_17–36. J Am Chem Soc 136: 5595–5598.    
• 154. Bhatia R, Lin H, Lal R (2000) Fresh and nonfibrillar amyloid b protein(1-42) induces rapid cellular degeneration in aged human fibroblasts: Evidence for AbP-channel-mediated cellular toxicity. FASEB 14: 1233–1243.    
• 155. Lin H, Bhatia R, Lal R (2001) Amyloid b protein forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB 15: 2433–2444.    
• 156. Lin H, Zhu YJ, Lal R (1999) Amyloid-b protein (1–40) forms calcium-permeable, Zn²⁺-sensitive channel in reconstituted lipid vesicles. Biochemistry 38: 11189–11196.    
• 157. Rhee SK, Quist AP, Lal R (1998) Amyloid b protein-(1-42) forms calcium-permeable, Zn²⁺-sensitive channel. J Biol Chem 273: 13379–13382.    
• 158. Parbhu A, Lin H, Thimm J, et al. (2002) Imaging real-time aggregation of amyloid β protein (1-42) by atomic force microscopy. Peptides 23: 1265–1270.    
• 159. Legleiter J, (2011) Assessing Aβ aggregation state by atomic force microscopy, In: Roberson ED (editor.), Alzheimer's Disease and Frontotemporal Dementia: Methods and Protocols, 57–70.
• 160. Kowalewski T, Holtzman DM (1999) In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation. Proc Natl Acad Sci USA 96: 3688–3693.    
• 161. Hane F, Drolle E, Gaikwad R, et al. (2011) Amyloid-β aggregation on model lipid membranes: An atomic force microscopy study. J Alzheimers Dis 26: 485–494.    
• 162. Legleiter J, Fryer JD, Holtzman DM, et al. (2011) The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. ACS Chem Neurosci 2: 588–599.    
• 163. Yip CM, Elton EA, Darabie AA, et al. (2001) Cholesterol, a modulator of membrane-associated Ab-fibrillogenesis and neurotoxicity. J Mol Biol 311: 723–734.    
• 164. Yip CM, McLaurin J (2001) Amyloid-b assembly: A critical step in fibrillogensis and membrane disruption. Biophys J 80: 1359–1371.    
• 165. Pifer PM, Yates EA, Legleiter J (2011) Point mutations in Aβ result in the formation of distinct polymorphic aggregates in the presence of lipid bilayers. PLoS One 6: e16248.    
• 166. Burke KA, Yates EA, Legleiter J (2013) Amyloid-forming proteins alter the local mechanical properties of lipid membranes. Biochemistry 52: 808–817.    
• 167. Hane F, Tran G, Attwood S, et al. (2013) Cu²⁺ affects amyloid-β (1-42) aggregation by increasing peptide-peptide binding forces. PLoS One 8: e59005.    
• 168. Kim BH, Palermo NY, Lovas S, et al. (2011) Single-molecule atomic force microscopy force spectroscopy study of Aβ-40 interactions. Biochemistry 50: 5154–5162.    
• 169. Banerjee S, Sun Z, Hayden EY, et al. (2017) Nanoscale dynamics of amyloid-β42 oligomers as revealed by high-speed atomic force microscopy. ACS Nano 11: 12202–12209.    
• 170. Yang T, Li S, Xu H, et al. (2017) Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci 37: 152–163.    
• 171. Ahmed M, Davis J, Aucoin D, et al. (2010) Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils. Nat Struct Mol Biol 17: 561–556.    
• 172. Chimon S, Shaibat MA, Jones CR, et al. (2007) Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. Nat Struct Mol Biol 14: 1157–1164.    
• 173. Stroud JC, Liu C, Teng PK, et al. (2012) Toxic fibrillar oligomers of amyloid-β have cross-β structure. P Natl Acad Sci USA 109: 7717–7722.    
• 174. Gu L, Liu C, Stroud JC, et al. (2014) Antiparallel triple-strand architecture for prefibrillar Aβ42 oligomers. J Biol Chem 289: 27300–27313.    
• 175. Teoh CL, Su D, Sahu S, et al. (2015) Chemical fluorescent probe for detection of Aβ oligomers. J Am Chem Soc 137: 13503–13509.    
• 176. Jameson LP, Dzyuba SV (2013) Aza-BODIPY: Improved synthesis and interaction with soluble Aβ1-42 oligomers. Bioorg Med Chem Lett 23: 1732–1735.    
• 177. Ono M, Watanabe H, Kimura H, et al. (2012) BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci 3: 319–324.    
• 178. Verwilst P, Kim HR, Seo J, et al. (2017) Rational design of in vivo Tau tangle-selective near-infrared fluorophores: expanding the BODIPY universe. J Am Chem Soc 139: 13393–13403.    

show all references